Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early and late-onset colorectal cancers: a case-case comparison of risk factors.

Cancer causes & control : CCC·2026
Same author

Optimizing reporting and outreach for surveillance and risk-reducing surgeries for cancer genetic predisposition: Findings of a workshop organized by the International Cascade Consortium.

Public health genomics·2026
Same author

Instability in Pentanucleotide Markers in a Subset of Microsatellite Instability-High Colorectal Cancer.

Current oncology (Toronto, Ont.)·2026
Same author

Sequencing approaches in hereditary cancer testing: strengths, limitations and future directions.

European journal of human genetics : EJHG·2026
Same author

Global Proteomic Analysis of Colorectal Cancers Stratified by Microsatellite Instability Subtype Reveals Protein Differences.

bioRxiv : the preprint server for biology·2026
Same author

A scalable new model of germline cancer genomic care delivery: Assessing psychological outcomes.

Genetics in medicine : official journal of the American College of Medical Genetics·2026

Related Experiment Video

Updated: Mar 2, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.2K

Multigene Panel Testing Provides a New Perspective on Lynch Syndrome.

Carin R Espenschied1, Holly LaDuca1, Shuwei Li1

  • 1Carin R. Espenschied, Holly LaDuca, Shuwei Li, Rachel McFarland, and Chia-Ling Gau, Ambry Genetics, Clinical Diagnostics, Aliso Viejo, CA; and Heather Hampel, The Ohio State University Comprehensive Cancer Center, Columbus, OH.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|May 18, 2017
PubMed
Summary

Lynch syndrome (LS) is often linked to colorectal and endometrial cancers. However, this study reveals MSH6 and PMS2 mutations are more common in MMR carriers and may indicate a hereditary breast cancer risk.

More Related Videos

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.8K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Related Experiment Videos

Last Updated: Mar 2, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.2K
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.8K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Area of Science:

  • Genetics
  • Oncology
  • Hereditary Cancer Syndromes

Background:

  • Lynch syndrome (LS) is primarily associated with MLH1 and MSH2 mutations, leading to high risks of colorectal cancer (CRC) and endometrial cancer.
  • Existing literature may be biased due to study cohorts focusing on patients with suspected hereditary CRC or population-based CRC/endometrial cancer data.

Purpose of the Study:

  • To characterize the phenotype of a large cohort of mismatch repair (MMR) mutation carriers identified through multigene panel testing.
  • To compare findings with previous studies and re-evaluate the understanding of Lynch syndrome and associated cancer risks.

Main Methods:

  • Retrospective review of clinical histories from 34,981 patients undergoing multigene panel testing (including MMR and EPCAM genes) between March 2012 and June 2015.
  • Statistical comparisons were performed on the identified MMR mutation carriers.

Main Results:

  • MSH6 mutations were the most frequent (followed by PMS2, MSH2, MLH1, EPCAM) among 528 MMR mutation carriers.
  • 11.9% of carriers had breast cancer only, and 27.3% had CRC only. MSH6 and PMS2 mutations were more prevalent in breast cancer-only cases compared to MLH1/MSH2.
  • A significant proportion of patients (22.2%) met BRCA1/2 testing criteria but not LS criteria, with MSH6/PMS2 mutations being more common in this group.

Conclusions:

  • Individuals with MSH6 and PMS2 mutations may exhibit a hereditary breast and ovarian cancer phenotype, challenging the traditional LS definition.
  • Current genetic testing criteria may be insufficient for identifying all patients at risk, underscoring the need for broader investigation of cancer risks in MMR mutation carriers.